Showing results (1361-1370 of 3,083) with videos related to
Sort By:
Pageof 309
Drug Safety|October 16, 2015
Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel DiseaseWilliam E BennettDrug Safety|September 16, 2015
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data from 10-Year Post-marketing SurveillanceFrancesca Renda, Giovanni Landoni, Renato Bertini Malgarini, et al.Drug Safety|September 20, 2015
Association of Attorney Advertising and FDA Action with Prescription Claims: A Time Series Segmented Regression AnalysisElizabeth C Tippett, Brian K ChenDrug Safety|September 20, 2015
Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health DataElizabeth E Roughead, Nicole L PrattDrug Safety|September 25, 2014
Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactionsMuhammad Amin, Naeti SuksomboonDrug Safety|September 27, 2014
Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS)Keith B Hoffman, Andrea R Demakas, Mo Dimbil, et al.Drug Safety|September 27, 2014
Relevance of foreign alerts and newsletters for the medication errors reporting programme in the Netherlands: an explorative retrospective studyKa-Chun Cheung, Patricia M L A van den Bemt, Marcel L Bouvy, et al.Drug Safety|August 6, 2015
Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS DatabaseManfred Hauben, Eric Y Hung, Kelly C Hanretta, et al.Drug Safety|August 13, 2014
Comparison of pregnancy and lactation labeling for attention-deficit hyperactivity disorder drugs marketed in Australia, the USA, Denmark, and the UKPernille Warrer, Lise Aagaard, Ebba Holme HansenDrug Safety|August 1, 2014
Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implicationsAlfonso E Bello, Robert J HoltPageof 309